Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study.

被引：0
|
作者：
Mustacchi, Giorgio
Pronzato, Paolo
D'Alonzo, Alessia
Mocerino, Carmela
Romagnoli, Emanuela
Garrone, Ornella
Blasi, Livio
De Laurentiis, Michelino
Michelotti, Andrea
Bologna, Alessandra
Giordano, Monica
Turletti, Anna
Montemurro, Filippo
De Placido, Sabino
Natoli, Clara
Taverniti, Cristiana
Biganzoli, Laura
Meattini, Icro
Marchetti, Paolo
Cazzaniga, Marina Elena
机构：
[1] Univ Trieste, Trieste, Italy
[2] San Martino IST Ist Naz Ric Cancr, Genoa, Italy
[3] Osped Policlin San Martino Oncol Med, Genoa, Italy
[4] AORN A Cardarelli Hosp, Naples, Italy
[5] Osped Macerata, UOC Oncol, Macerata, Italy
[6] S Croce & Carle Teaching Hosp, Med Oncol, Cuneo, Italy
[7] Fdn San Raffaele Giglio, Palerio, Italy
[8] Fdn Pascale, Breast Unit, Naples, Italy
[9] Azienda Osped Univ Pisana, Oncol Unit 1, Pisa, Italy
[10] IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[11] Santa Anna Hosp, Como, Italy
[12] ASLTO1 Osped Martini, Med Oncol, Turin, Italy
[13] Invest Clin Oncol Candiolo Canc Inst FPO IRCCS, Candiolo, Italy
[14] Univ Naples Federico II, Naples, Italy
[15] Univ G dAnnunzio, Dept Expt & Clin Sci, Chieti, Italy
[16] AOU Citta Salute & Sci, Med Oncol, Turin, Italy
[17] Hosp Prato, Sandro Pitigliani Med Oncol Dept, Prato, Italy
[18] Univ Florence, Florence, Italy
[19] Sapienza Univ Rome, S Andrea Hosp, Rome, Italy
[20] Hosp San Gerardo, Oncol Unit, Monza, MB, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13078
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
    Chan, Edmond Mankee
    Hong, Theodore S.
    Clark, Jeffrey William
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Zhu, Andrew
    Goyal, Lipika
    Murphy, Janet E.
    Kwak, Eunice L.
    Wo, Jennifer Y.
    Ryan, David P.
    Faris, Jason Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [42] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)
    Sun, Tao
    Zhang, Liang
    CANCER RESEARCH, 2023, 83 (05)
  • [44] A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)
    Zhang, Liang
    Sun, Tao
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Comparative effectiveness of early-line nab-paclitaxel (nab-P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A US real-world analysis
    Braiteh, Fadi S.
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [46] nab-paclitaxel (nab-P) plus nivolumab (Nivo) in human epidermal growth factor receptor 2 (HER2)-negative recurrent metastatic breast cancer (MBC)
    Waterhouse, D.
    Gutierrez, M.
    Bekaii-Saab, T.
    DeRosa, W.
    Wainberg, Z.
    George, B.
    Fraser, C. Duval
    Ko, A.
    Pierce, D. W.
    Stergiopoulos, S.
    Soliman, H.
    CANCER RESEARCH, 2016, 76
  • [47] Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian "real life" study
    Giordano, G.
    Febbraro, A.
    Vaccaro, V.
    Zagonel, V.
    De Giorgi, U.
    Melisi, D.
    Vasile, E.
    Bianco, R.
    Lo Re, G.
    Valente, M.
    Formica, V.
    Montesarchio, V.
    Maiorino, L.
    Sanna, G.
    Bittoni, A.
    Ricci, V.
    Santini, D.
    Zaniboni, A.
    Milella, M.
    De Vita, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S444 - S444
  • [48] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study
    Cazzaniga, M.
    Cagossi, K.
    Valerio, M. R.
    Russo, S.
    Casadei, V.
    Scognamiglio, G.
    Cavanna, L.
    Toniolo, D.
    De Conciliis, E.
    Melegari, E.
    Stocchi, L.
    Gebbia, V.
    Vandone, A. M.
    Cursano, M. C.
    Pinotti, G.
    Rossello, R.
    Ortu, S.
    Pellegrino, B.
    Saracchini, S.
    Torri, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
    Dotan, Efrat
    Cardin, Dana Backlund
    Lenz, Heinz-Josef
    Messersmith, Wells A.
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Kapoun, Ann M.
    Brachmann, Rainer Karl
    Uttamsingh, Shailaja
    Weekes, Colin D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) plus carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
    Gajra, A.
    Ali, H.
    Amiri, K. I.
    Karim, N. Abdel
    Matrana, M. R.
    Mulford, D.
    Ong, T. J.
    Sanford, A.
    Santos, E.
    Socinski, M.
    Spigel, D. R.
    Lilenbaum, R. C.
    ANNALS OF ONCOLOGY, 2016, 27
12345